The FDA has begun soliciting feedback to inform the next version of the Prescription Drug User Fee Act. User fees remain ...

A 28-year-old woman was admitted to the hospital because of severe hypoxemia and right heart failure that had been caused by ...

A small-molecule drug proves its mettle in the treatment of spinal muscular atrophy, a disease amenable to intervention at the pre-mRNA level.

Though infant mortality has continuously been targeted by health policy agendas, policies tend to place it in an individualistic and narrow frame, failing to consider and address its structural ...

To prevent the spread of inaccurate information, academic and health care institutions will need to equip scientists and clinicians to engage effectively on nontraditional media platforms.

The need to suppress a patient’s immune system after the transplantation of allogeneic cells is associated with wide-ranging side effects. We report the outcomes of transplantation of ...

The author describes the scientific foundations of a clinical trial of a first-in-class small-molecule estrogen receptor degrader to treat patients with metastatic breast cancer.

Although xenon may have neuroprotective effects, there is no strong evidence that it aids in short-term, high-altitude performance. Success is more likely a result of acclimatization, oxygen suppor ...

The rising tide of chronic kidney disease among patients with type 2 diabetes continues to challenge clinicians and health systems worldwide.1 Advances have been made in the management of chronic k ...

To the Editor: In the 2IQP trial, Kudva and colleagues (May 8 issue) 1 found that in adults with insulin-treated type 2 diabetes, automated insulin delivery (AID) led to a greater reduction in ...

“Corporatization” of health care, a process predicted decades ago, now refers to the general trend throughout the industry toward higher levels of integrated control by consolidated profit-seeking ...

Audio Interview from the New England Journal of Medicine — Interview with Nancy Tomes on the century-long transition to a corporate business model in U.S. health care.